Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-activeLactobacillus reuteriNCIMB 30242 yoghurt formulation in hypercholesterolaemic adults
- 9 November 2011
- journal article
- research article
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 107 (10), 1505-1513
- https://doi.org/10.1017/s0007114511004703
Abstract
Several studies have reported limited or no reduction in serum cholesterol in response to probiotic formulations. Recently, probiotics have shown promise in treating metabolic disease due to improved strain selection and delivery technologies. The aim of the present study was to evaluate the cholesterol-lowering efficacy of a yoghurt formulation containing microencapsulated bile salt hydrolase (BSH)-activeLactobacillus reuteriNCIMB 30242, taken twice per d over 6 weeks, in hypercholesterolaemic adults. A total of 114 subjects completed this double-blind, placebo-controlled, randomised, parallel-arm, multi-centre study. This interventional study included a 2-week washout, 2-week run-in and 6-week treatment period. Subjects were randomised to consume either yoghurts containing microencapsulatedL. reuteriNCIMB 30242 or placebo yoghurts. Over the intervention period, subjects consuming yoghurts containing microencapsulatedL. reuteriNCIMB 30242 attained significant reductions in LDL-cholesterol (LDL-C) of 8·92 % (P = 0·016), total cholesterol (TC) of 4·81 % (P = 0·031) and non-HDL-cholesterol (HDL-C) of 6·01 % (P = 0·029) over placebo, and a significant absolute change in apoB-100 of − 0·19 mmol/l (P = 0·049). Serum concentrations of TAG and HDL-C were unchanged over the course of the study. Present results show that consumption of microencapsulated BSH-activeL. reuteriNCIMB 30242 yoghurt is efficacious and safe for lowering LDL-C, TC, apoB-100 and non-HDL-C in hypercholesterolaemic subjects. The efficacy of microencapsulated BSH-activeL. reuteriNCIMB 30242 yoghurts appears to be superior to traditional probiotic therapy and akin to that of other cholesterol-lowering ingredients.Keywords
This publication has 50 references indexed in Scilit:
- Orally Delivered Microencapsulated Live Probiotic Formulation Lowers Serum Lipids in Hypercholesterolemic HamstersJournal of Medicinal Food, 2009
- Lowering Low-Density Lipoprotein Cholesterol: Statins, Ezetimibe, Bile Acid Sequestrants, and Combinations: Comparative Efficacy and SafetyEndocrinology and Metabolism Clinics of North America, 2009
- Microencapsulated bile salt hydrolase producing Lactobacillus reuteri for oral targeted delivery in the gastrointestinal tractApplied Microbiology and Biotechnology, 2008
- Investigation of Microencapsulated BSH ActiveLactobacillusin the Simulated Human GI TractJournal of Biomedicine and Biotechnology, 2007
- Ezetimibe (Zetia): A New Type of Lipid-Lowering AgentBaylor University Medical Center Proceedings, 2003
- Simultaneous quantitation of fatty acids, sterols and bile acids in human stool by capillary gas–liquid chromatographyJournal of Chromatography B, 2002
- Statins: mechanism of action and effectsJournal of Cellular and Molecular Medicine, 2001
- Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statinsAmerican Journal Of Medicine, 2001
- Global mortality, disability, and the contribution of risk factors: Global Burden of Disease StudyThe Lancet, 1997
- Pregnancy and breast cancerThe Lancet, 1994